New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation

被引：0
|
作者：
Yalin Liu
Xianghang Luo
机构：
[1] Xiangya Hospital of Central South University,Department of Endocrinology, Endocrinology Research Center
[2] Xiangya Hospital of Central South University,National Clinical Research Center for Geriatric Disorders
来源：
Frontiers of Medicine | 2022年 / 16卷
关键词：
semaglutide; type 2 diabetes; obesity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
引用
收藏
页码：17 / 24
页数：7
相关论文
共 50 条
  • [1] New practice in semaglutide on type-2 diabetes and obesity:clinical evidence and expectation
    Yalin Liu
    Xianghang Luo
    [J]. Frontiers of Medicine, 2022, 16 (01) : 17 - 24
  • [2] New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
    Liu, Yalin
    Luo, Xianghang
    [J]. FRONTIERS OF MEDICINE, 2022, 16 (01) : 17 - 24
  • [3] Semaglutide is effective in type 2 diabetes and obesity with schizophrenia
    Kaoru Noda
    Takehiro Kato
    Nao Nomura
    Mayu Sakai
    Sodai Kubota
    Tokuyuki Hirose
    Yanyan Liu
    Yoshihiro Takahashi
    Ken Takao
    Masami Mizuno
    Takuo Hirota
    Tetsuya Suwa
    Yukio Horikawa
    Daisuke Yabe
    [J]. Diabetology International, 2022, 13 : 693 - 697
  • [4] Semaglutide is effective in type 2 diabetes and obesity with schizophrenia
    Noda, Kaoru
    Kato, Takehiro
    Nomura, Nao
    Sakai, Mayu
    Kubota, Sodai
    Hirose, Tokuyuki
    Liu, Yanyan
    Takahashi, Yoshihiro
    Takao, Ken
    Mizuno, Masami
    Hirota, Takuo
    Suwa, Tetsuya
    Horikawa, Yukio
    Yabe, Daisuke
    [J]. DIABETOLOGY INTERNATIONAL, 2022, 13 (04) : 693 - 697
  • [5] Obesity and type-2 diabetes in the elderly
    Dewan, S
    Wilding, JPH
    [J]. GERONTOLOGY, 2003, 49 (03) : 137 - 145
  • [6] FROM OBESITY TO TYPE-2 DIABETES
    SCHEEN, AJ
    [J]. ACTA CLINICA BELGICA, 1992, 47 : 30 - 36
  • [7] SEMAGLUTIDE FOR THE MANAGEMENT OF TYPE 2 DIABETES: CLINICAL EVIDENCE, CARDIOPROTECTIVE EFFECTS, AND GUIDELINES
    Kobalava, Zh D.
    Kokhan, E., V
    [J]. KARDIOLOGIYA, 2020, 60 (09) : 122 - 133
  • [8] Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide
    Lichert, Frank
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (06)
  • [9] Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes
    Cohen, Charlotte
    Cohen, Regis
    Sabouret, Pierre
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 380 - 382
  • [10] Obesity and Diabetes: The Impact of Bariatric Surgery on Type-2 Diabetes
    John B. Dixon
    [J]. World Journal of Surgery, 2009, 33
12345